Heather Knowles

597 total citations
15 papers, 495 citations indexed

About

Heather Knowles is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Dermatology. According to data from OpenAlex, Heather Knowles has authored 15 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Dermatology. Recurrent topics in Heather Knowles's work include PI3K/AKT/mTOR signaling in cancer (10 papers), Lung Cancer Treatments and Mutations (4 papers) and Cutaneous lymphoproliferative disorders research (3 papers). Heather Knowles is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (10 papers), Lung Cancer Treatments and Mutations (4 papers) and Cutaneous lymphoproliferative disorders research (3 papers). Heather Knowles collaborates with scholars based in United States, Italy and Slovakia. Heather Knowles's co-authors include Victor M. Rivera, Camille L. Bedrosian, Monica Mita, Eric K. Rowinsky, Alain C. Mita, Anthony W. Tolcher, Gerald J. Fetterly, Theresa A. Mays, Quincy S. Chu and Alejandro D. Ricart and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

Heather Knowles

15 papers receiving 483 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heather Knowles United States 11 336 162 147 83 62 15 495
Lorina Dudkin United States 5 506 1.5× 156 1.0× 160 1.1× 117 1.4× 89 1.4× 5 647
Qing-Rong Chen United States 9 289 0.9× 140 0.9× 105 0.7× 54 0.7× 93 1.5× 9 484
Angela Tam United States 9 426 1.3× 159 1.0× 115 0.8× 48 0.6× 71 1.1× 12 634
Saradhi Mallampati United States 14 275 0.8× 94 0.6× 155 1.1× 34 0.4× 81 1.3× 34 592
Ceren Gönen Korkmaz Norway 10 226 0.7× 142 0.9× 84 0.6× 27 0.3× 82 1.3× 14 450
Rebecca L. Lynch United States 4 452 1.3× 98 0.6× 143 1.0× 89 1.1× 88 1.4× 4 615
Adekunle Raji United States 9 218 0.6× 75 0.5× 156 1.1× 76 0.9× 140 2.3× 17 395
Flora Luo United States 7 205 0.6× 103 0.6× 100 0.7× 62 0.7× 47 0.8× 9 390
Donald P. Lesslie United States 8 397 1.2× 87 0.5× 353 2.4× 71 0.9× 125 2.0× 11 687
Louise Barys Switzerland 8 328 1.0× 105 0.6× 157 1.1× 53 0.6× 62 1.0× 12 575

Countries citing papers authored by Heather Knowles

Since Specialization
Citations

This map shows the geographic impact of Heather Knowles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather Knowles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather Knowles more than expected).

Fields of papers citing papers by Heather Knowles

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather Knowles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather Knowles. The network helps show where Heather Knowles may publish in the future.

Co-authorship network of co-authors of Heather Knowles

This figure shows the co-authorship network connecting the top 25 collaborators of Heather Knowles. A scholar is included among the top collaborators of Heather Knowles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather Knowles. Heather Knowles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Hartford, Christine, Apurva A. Desai, Linda Janisch, et al.. (2009). A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies. Clinical Cancer Research. 15(4). 1428–1434. 71 indexed citations
2.
Mita, Monica, Alain C. Mita, Quincy S. Chu, et al.. (2008). Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies. Journal of Clinical Oncology. 26(3). 361–367. 227 indexed citations
3.
Janisch, Linda, Anjali Desai, Monica Mita, et al.. (2005). PTEN expression in archival tumor samples in patients (pts) with advanced malignancies in two phase I studies of AP23573 (AP), an mTOR inhibitor. Journal of Clinical Oncology. 23(16_suppl). 9661–9661. 1 indexed citations
4.
Rivera, Victor M., Jeffrey I. Kreisberg, Monica Mita, et al.. (2005). Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. Journal of Clinical Oncology. 23(16_suppl). 3033–3033. 12 indexed citations
5.
Desai, Anjali, Gerald J. Fetterly, Heather Knowles, et al.. (2005). Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor. Journal of Clinical Oncology. 23(16_suppl). 3043–3043. 5 indexed citations
6.
Desai, Apurva A., Linda Janisch, Lori Berk, et al.. (2004). 390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. European Journal of Cancer Supplements. 2(8). 117–117. 1 indexed citations
7.
Desai, Anjali, Linda Janisch, Heather Knowles, et al.. (2004). A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Journal of Clinical Oncology. 22(14_suppl). 3150–3150. 22 indexed citations
8.
Mita, Monica, Eric K. Rowinsky, Akira Mita, et al.. (2004). Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. Journal of Clinical Oncology. 22(14_suppl). 3076–3076. 34 indexed citations
9.
Desai, Anjali, Linda Janisch, Heather Knowles, et al.. (2004). A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Journal of Clinical Oncology. 22(14_suppl). 3150–3150. 16 indexed citations
10.
Rowinsky, Eric K., Alain C. Mita, S. Syed, et al.. (2004). 409 AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies — a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study. European Journal of Cancer Supplements. 2(8). 122–122. 3 indexed citations
11.
Mita, Monica, Alain C. Mita, Heather Knowles, et al.. (2004). Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. Journal of Clinical Oncology. 22(14_suppl). 3076–3076. 15 indexed citations
12.
Cipriani, Barbara, Lanfen Chen, Kenji Hiromatsu, et al.. (2003). Upregulation of Group 1 CD1 Antigen Presenting Molecules in Guinea Pigs with Experimental Autoimmune Encephalomyelitis: An Immunohistochemical Study. Brain Pathology. 13(1). 1–9. 20 indexed citations
13.
Cipriani, Barbara, Heather Knowles, Lanfen Chen, Luca Battistini, & Celia F. Brosnan. (2002). Involvement of Classical and Novel Protein Kinase C Isoforms in the Response of Human Vγ9Vδ2 T Cells to Phosphate Antigens. The Journal of Immunology. 169(10). 5761–5770. 17 indexed citations
14.
Cipriani, Barbara, Giovanna Borsellino, Heather Knowles, et al.. (2001). Curcumin Inhibits Activation of Vγ9Vδ2 T Cells by Phosphoantigens and Induces Apoptosis Involving Apoptosis-Inducing Factor and Large Scale DNA Fragmentation. The Journal of Immunology. 167(6). 3454–3462. 40 indexed citations
15.
Downen, Martha, Stanley M. Belkowski, Heather Knowles, Marina Cardillo, & Michael B. Prystowsky. (1999). Developmental expression of voltage-gated potassium channel β subunits. Developmental Brain Research. 117(1). 71–80. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lorina Dudkin Breakdown of academic impact, for papers by Qing-Rong Chen Breakdown of academic impact, for papers by Angela Tam Breakdown of academic impact, for papers by Saradhi Mallampati Breakdown of academic impact, for papers by Ceren Gönen Korkmaz Breakdown of academic impact, for papers by Rebecca L. Lynch Breakdown of academic impact, for papers by Adekunle Raji Breakdown of academic impact, for papers by Flora Luo Breakdown of academic impact, for papers by Donald P. Lesslie Breakdown of academic impact, for papers by Louise Barys
Rankless by CCL
2026